"At Quintiles, we are focused on leading our customers through an increasingly complex and ever-changing drug development landscape," said Paula Brown Stafford, president of Clinical Development at Quintiles. "We are delighted once again to be recognised as the industry leader in Phase II/III research. This distinction is a result of the work of our tremendous teams around the world and underscores our unique ability to connect insights, expertise and capabilities across our organisation to improve the probability of success for our customers."

In the survey, Quintiles outperformed all other large CROs across all customer loyalty-related measures, which are defined by overall satisfaction, willingness to recommend, and likelihood to use Quintiles again. Quintiles also rated higher than all large CROs in a number of selection criteria, including:

• Breadth of services
• Therapeutic expertise
• Commercial market, local market and regulatory knowledge
• Data quality
• Technology for real-time data access
• Speed of site start-up
• Patient recruitment strategy

Survey respondents were decision-makers with large, mid-size and small biopharmaceutical companies who were involved in outsourced clinical study activities and Phase II/III clinical trials within the past 18 months. More information about the ISR report is available here.